HIV tropism and decreased risk of breast cancer

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Hessol, Nancy A ^a   Napolitano, Laura A ^b,c   Smith, Dawn ^d   Lie, Yolanda ^b   Levine, Alexandra ^e,l   Young, Mary ^f   Cohen, Mardge ^g   Minkoff, Howard ^h   Anastos, Kathryn ⁱ   D'Souza, Gypsyamber ^j   Greenblatt, Ruth M ^a   Goedert, James J ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g RUSH UNIVERSITY   (United States)

^h SUNY DOWNSTATE MEDICAL CENTER   (United States)

ⁱ MONTEFIORE MEDICAL CENTER   (United States)

^j JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

^l UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CXCR4; VIRUS ENVELOPE PROTEIN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5;

ADULT; ARTICLE; BLOOD ANALYSIS; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENOPAUSE; PHENOTYPIC VARIATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; VIRUS LOAD; BIOSYNTHESIS; BREAST TUMOR; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; MULTICENTER STUDY; PROSPECTIVE STUDY; RISK; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS;

ADULT; ANTIGENS, CD4; BREAST NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; LONGITUDINAL STUDIES; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, CCR5; RECEPTORS, CXCR4; RISK; RISK FACTORS;

EID: 78650729128     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014349     Document Type: Article

References (29)

1. Weber J, Piontkivska H, Quinones-Mateu ME (2006) HIV type 1 tropism and inhibitors of viral entry: clinical implications. AIDS Rev 8(2): 60-77.
2. Frisch M, Biggar RJ, Engels EA, Goedert JJ; AIDS-Cancer Match Registry Study Group (2001) Association of cancer with AIDS-related immunosuppression in adults. JAMA 285(13): 1736-45.
3. Goedert JJ, Schairer C, McNeel TS, Hessol NA, Rabkin CS, et al. (2006) Risk of breast, ovary, and uterine corpus cancers among 85,268 women with AIDS. Br J Cancer 95(5): 642-8.
4. Luker KE, Luker GD (2006) Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett 238(1): 30-41.
5. Muller A, Homey B, Soto H, Ge N, Catron D, et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824): 50-6.
6. Schmid BC, Rudas M, Rezniczek GA, Leodolter S, Zeillinger R (2004) CXCR4 is expressed in ductal carcinoma in situ of the breast and in atypical ductal hyperplasia. Breast Cancer Res Treat 84(3): 247-50.
7. Burger JA, Kipps TJ (2006) CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107(5): 1761-7.
8. Liang Z, Brooks J, Willard M, Liang K, Yoon Y, et al. (2007) CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun 359(3): 716-22.
9. Sauve K, Lepage J, Sanchez M, Heveker N, Tremblay A (2009) Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Cancer Res 69(14): 5793-800.
10. Endo M, Inatsu A, Hashimoto K, Takamune N, Shoji S, et al. (2008) Human immunodeficiency virus-induced apoptosis of human breast cancer cells via CXCR4 is mediated by the viral envelope protein but does not require CD4. Curr HIV Res 6(1): 34-42.
11. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, et al. (1998) WIHS Collaborative Study Group. Epidemiology 1998; 9(2): 117-25.
12. Bacon MC, von Wyl V, Alden C, Sharp G, Robison E, et al. (2005) The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol 12(9): 1013-9.
13. Smith DK, Warren DL, Vlahov D, Schuman P, Stein MD, et al. (1997) Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort study of human immunodeficiency virus infection in US women. Am J Epidemiol 146(6): 459-69.
14. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, et al. (2008) Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 359(14): 1429-41.
15. SAS Institute Inc, ed. (2008) SAS/STAT User's Guide, Version 9.2. CaryNorth Carolina: SAS Institute Inc.
16. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, et al. (2003) In vitro propagation and transcriptional profiling of human mammary stem/ progenitor cells. Genes Dev 17(10): 1253-70.
17. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, et al. (2003) A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 63(23): 8360-5.
18. Ahr B, Robert-Hebmann V, Devaux C, Biard-Piechaczyk M (2004) Apoptosis of uninfected cells induced by HIV envelope glycoproteins. Retrovirology 1: 12.
19. Baribaud F, Edwards TG, Sharron M, Brelot A, Heveker N, et al. (2001) Antigenically distinct conformations of CXCR4. J Virol 75(19): 8957-67.
20. Toniolo A, Serra C, Conaldi PG, Basolo F, Falcone V, et al. (1995) Productive HIV-1 infection of normal human mammary epithelial cells. AIDS 9(8): 859-66.
21. Preston-Martin S, Kirstein LM, Pogoda JM, Rimer B, Melnick S, et al. (2002) Use of mammographic screening by HIV-infected women in the Women's Interagency HIV Study (WIHS) Prev Med 34(3): 386-92.
22. Chaturvedi AK, Mbulaiteye SM, Engels EA (2008) Underestimation of relative risks by standardized incidence ratios for AIDS-related cancers. Ann Epidemiol 18(3): 230-4.
23. Colditz GA, Rosner B (2000) Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 152(10): 950-64.
24. Smith JR, Falkenhagen KM, Coupland SE, Chipps TJ, Rosenbaum JT, et al. (2007) Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1. Am J Clin Pathol 127(4): 633-41.
25. Uccini S, Scarpino S, Ballarini F, Soriani A, Chilosi M, et al. (2003) In situ study of chemokine and chemokine-receptor expression in Kaposi sarcoma. Am J Dermatopathol 25(5): 377-83.
26. Hatse S, Princen K, Bridger G, De Clercq E, Schols D (2002) Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 527(1-3): 255-62.
27. Moyle G, DeJesus E, Boffito M, Wong RS, Gibney C, et al. (2009) Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1. Clin Infect Dis 48(6): 798-805.
28. Thoma G, Streiff MB, Kovarik J, Glickman F, Wagner T, et al. (2008) Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo. J Med Chem 51(24): 7915-20.
29. Iwasaki Y, Akari H, Murakami T, Kumakura S, Dewan MZ, et al. (2009) Efficient inhibition of SDF-1alpha-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists. Cancer Sci 100(4): 778-81.